News

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

WHEN MOTHERS SHUT DOWN THE FATHERS’ GENES IN THE EMBRYO

Bacteria provide immunity against giant viruses

Notfallsystem bei Nervenzellen entdeckt

COVID-19-assoziierte Pilzinfektion: Große internationale Studie identifiziert immunologische Mechanismen und klinische Risikofaktoren

Neuer Wirkstoff erweitert Therapiespektrum bei Rheumatoider Arthritis

Vast paleogenetic study reveals insights on migration patterns, the expansion of farming and language development from the Caucasus over western Asia and Southern Europe from the early Copper Age until the late middle ages

TILT COMPENSATION MAXIMIZES PRECISION IN 2PP 3D-PRINTING

Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense

Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate

Valneva Reports H1 2022 Results and Provides Corporate Updates

Evercyte human cells as in vitro test systems

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates

F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Brustkrebs: Neuer Wirkstoff lässt Gehirnmetastasen schrumpfen

Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Kinder mit Krebs reden täglich bei Therapie mit

QUANTRO Therapeutics kooperiert mit Boehringer Ingelheim in der Entwicklung von Wirkstoffkandidaten zur Transkriptionsregulation